Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fauchais, A-L
Right arrow Articles by Hatron, P-Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fauchais, A-L
Right arrow Articles by Hatron, P-Y
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 13, No. 4, 245-248 (2004)
DOI: 10.1191/0961203304lu1006oa

Antiphospholipid antibodies in primary Sjögren’s syndrome: prevalence and clinical significance in a series of 74 patients

A-L Fauchais

Department of Internal Medicine, Regional University Hospital of Lille, France, alfauchais{at}caramail.com

M Lambert

Department of Internal Medicine, Regional University Hospital of Lille, France

D Launay

Department of Internal Medicine, Regional University Hospital of Lille, France

U Michon-Pasturel

Department of Internal Medicine, Regional University Hospital of Lille, France

V Queyrel

Department of Internal Medicine, Regional University Hospital of Lille, France

N Nguyen

Department of Internal Medicine, Regional University Hospital of Lille, France

M Hebbar

Department of Internal Medicine, Regional University Hospital of Lille, France

E Hachulla

Department of Internal Medicine, Regional University Hospital of Lille, France

B Devulder

Department of Internal Medicine, Regional University Hospital of Lille, France

P-Y Hatron

Department of Internal Medicine, Regional University Hospital of Lille, France

The aim of this study is to determine prevalence, clinical significance of antiphospholipidantibodies (aPL) including anticardiolipin antibodies (aCL), anti-b2GP1 and lupus anticoagulant (LA) in a cohort of 74 patients with primary Sjögren’s syndrome (pSS) according to revised European criteria. aPL were found in 25 (34%) patients; IgG in 23 (12 had low titres, six moderate titres and five high titres) and IgM in five (three and two had respectively moderate and high titres). Eight (11%) patients were found to have LA; anti-b2GP1 antibodies were detected only in three (4%) patients. Only two patients with LA, aPL and b2GP1 had recurrent venous thrombosis. One patient with moderate titres of aPL exhibited recurrent spontaneous foetal losses. Peripheral neuropathies without cryoglobulinemia were more frequent in the aPL group. Other systemic involvements of pSS were the same in both groups with or without aPL. Patients with aPL have more concurrentimmunological diseases such as thyroiditis and primary biliary cirrhosis and a higher prevalence of hypergammaglobulinemia (P < 0.05). Even if aPL prevalence reached 30% in pSS, titres were usually low, with a close correlation with hypergammaglobulinemia but not with antiphospholipid syndrome, which is related to positivity of both LA and aPL.

Key Words: antiphospholipid antibodies • hypergammaglobulinemia • Sjögren’s syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
LupusHome page
I Uthman, I Salti, and M Khamashta
Endocrinologic Manifestations of the Antiphospholipid Syndrome
Lupus, August 1, 2006; 15(8): 485 - 489.
[Abstract] [PDF]